"CD146 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell adhesion molecule of the immunoglobulin superfamily that is expressed by ENDOTHELIAL CELLS where it functions to stabilize INTERCELLULAR JUNCTIONS. It is also highly expressed by melanoma tumor cells and may facilitate their METASTASIS.
| Descriptor ID |
D051929
|
| MeSH Number(s) |
D12.776.395.550.200.170 D12.776.543.550.200.140 D12.776.624.301.249 D23.050.285.439.249 D23.050.301.350.150
|
| Concept/Terms |
CD146 Antigen- CD146 Antigen
- Antigen, CD146
- S-Endo 1 Endothelial-Associated Antigen
- Melanoma Cell Adhesion Molecule
- CD146 Antigens
- Antigens, CD146
- Gicerin
- Glycoprotein MUC18
- MUC18, Glycoprotein
|
Below are MeSH descriptors whose meaning is more general than "CD146 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CD146 Antigen".
This graph shows the total number of publications written about "CD146 Antigen" by people in this website by year, and whether "CD146 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD146 Antigen" by people in Profiles.
-
Wnt5a signaling induced phosphorylation increases APT1 activity and promotes melanoma metastatic behavior. Elife. 2018 04 12; 7.
-
Promoter methylation of MCAM, ERa and ERß in serum of early stage prostate cancer patients. Oncotarget. 2017 Feb 28; 8(9):15431-15440.
-
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol. 2006 Mar 20; 24(9):1449-53.
-
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24.
-
Serum C-reactive protein and circulating endothelial cells in patients with acute myocardial infarction. Clin Hemorheol Microcirc. 2005; 32(4):287-96.